14.38
price down icon0.35%   -0.05
after-market Dopo l'orario di chiusura: 14.38
loading
Precedente Chiudi:
$14.43
Aprire:
$14.39
Volume 24 ore:
287.73K
Relative Volume:
0.44
Capitalizzazione di mercato:
$584.05M
Reddito:
-
Utile/perdita netta:
$-168.05M
Rapporto P/E:
-2.8031
EPS:
-5.13
Flusso di cassa netto:
$-146.15M
1 W Prestazione:
+0.14%
1M Prestazione:
+4.89%
6M Prestazione:
+21.45%
1 anno Prestazione:
-70.99%
Intervallo 1D:
Value
$14.19
$14.74
Intervallo di 1 settimana:
Value
$13.64
$14.74
Portata 52W:
Value
$9.12
$72.37

Keros Therapeutics Inc Stock (KROS) Company Profile

Name
Nome
Keros Therapeutics Inc
Name
Telefono
617-314-6297
Name
Indirizzo
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Name
Dipendente
163
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-04
Name
Ultimi documenti SEC
Name
KROS's Discussions on Twitter

Confronta KROS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
KROS
Keros Therapeutics Inc
14.38 586.08M 0 -168.05M -146.15M -5.13
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-06-10 Downgrade BofA Securities Buy → Neutral
2025-01-21 Downgrade Cantor Fitzgerald Overweight → Neutral
2025-01-17 Downgrade Wedbush Outperform → Neutral
2024-12-16 Downgrade Guggenheim Buy → Neutral
2024-12-16 Reiterato Oppenheimer Outperform
2024-12-13 Reiterato H.C. Wainwright Buy
2024-12-12 Downgrade BTIG Research Buy → Neutral
2024-12-12 Downgrade TD Cowen Buy → Hold
2024-12-12 Downgrade William Blair Outperform → Mkt Perform
2024-11-05 Iniziato Jefferies Buy
2024-10-24 Iniziato Cantor Fitzgerald Overweight
2024-10-16 Iniziato Scotiabank Sector Outperform
2024-09-23 Iniziato Guggenheim Buy
2024-06-25 Iniziato Oppenheimer Outperform
2024-02-21 Iniziato William Blair Outperform
2023-12-08 Iniziato Wells Fargo Overweight
2023-07-31 Iniziato Wedbush Outperform
2023-07-26 Iniziato BofA Securities Buy
2023-02-14 Iniziato Cowen Outperform
2022-10-18 Iniziato Truist Buy
2022-07-26 Iniziato BTIG Research Buy
2020-12-08 Reiterato H.C. Wainwright Buy
2020-05-04 Iniziato H.C. Wainwright Buy
2020-05-04 Iniziato Jefferies Buy
2020-05-04 Iniziato Piper Sandler Overweight
2020-05-04 Iniziato SVB Leerink Outperform
Mostra tutto

Keros Therapeutics Inc Borsa (KROS) Ultime notizie

pulisher
Jul 24, 2025

How high can Keros Therapeutics Inc. stock price go in 2025Consistent high-performance stocks - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

Is Keros Therapeutics Inc. a good long term investmentExplosive wealth accumulation - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Keros Therapeutics Inc. stock priceHigh-profit trading signals - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Keros Therapeutics Inc. stockFast-track wealth growth - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Keros Therapeutics Inc. Stock Analysis and ForecastTriple-digit profit margins - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

(KROS) Trading Signals - news.stocktradersdaily.com

Jul 19, 2025
pulisher
Jul 18, 2025

Should I buy Keros Therapeutics Inc. stock before earningsHigh Confidence Trade Setups - Newser

Jul 18, 2025
pulisher
Jul 17, 2025

Keros Therapeutics Begins Phase 3 Trial for Elritercept - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Keros Therapeutics doses first patient in Phase 3 MDS trial By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept - The Manila Times

Jul 17, 2025
pulisher
Jul 17, 2025

Keros Therapeutics doses first patient in Phase 3 MDS trial - Investing.com

Jul 17, 2025
pulisher
Jul 16, 2025

Why Keros Therapeutics Inc. stock attracts strong analyst attentionLow Drawdown Trade Signals - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

How Keros Therapeutics Inc. stock performs during market volatilityFree Signals Group - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Keros Therapeutics Inc. stock price move sharplyFree Trading Strategy Suggestions - Newser

Jul 15, 2025
pulisher
Jul 09, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $30.56 Average Target Price from Brokerages - MarketBeat

Jul 09, 2025
pulisher
Jul 09, 2025

Trend Tracker for (KROS) - news.stocktradersdaily.com

Jul 09, 2025
pulisher
Jul 08, 2025

Sarcopenia Market Expected to Experience Major Growth by 2034, According to DelveInsight | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross - Barchart.com

Jul 08, 2025
pulisher
Jul 06, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World

Jul 06, 2025
pulisher
Jun 30, 2025

Keros Therapeutics, Inc.(NasdaqGM: KROS) dropped from Russell 3000 Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 2000 Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 18, 2025

(KROS) Trading Report - news.stocktradersdaily.com

Jun 18, 2025
pulisher
Jun 17, 2025

Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - MSN

Jun 17, 2025
pulisher
Jun 16, 2025

Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace

Jun 16, 2025
pulisher
Jun 14, 2025

Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $30.56 - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

Bank of America Downgrades Keros Therapeutics (NASDAQ:KROS) to Neutral - MarketBeat

Jun 13, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Buys 23,342 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Jun 13, 2025
pulisher
Jun 12, 2025

Keros Therapeutics (NASDAQ:KROS) Shares Gap DownTime to Sell? - MarketBeat

Jun 12, 2025
pulisher
Jun 11, 2025

Keros Therapeutics (NASDAQ:KROS) Downgraded to Neutral Rating by Bank of America - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst - Benzinga

Jun 10, 2025

Keros Therapeutics Inc Azioni (KROS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):